Terkko Navigator / Yki-Järvinen, H(annele)*

rs641738C>T near MBOAT7 is associated with liver fat, ALT, and fibrosis in NAFLD: a meta-analysis.

Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults.

MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.

The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue.

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.

Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease.

Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.

Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling.

Ceramides - a cause of insulin resistance in NAFLD in both murine models and humans.

Reply to Krahn and Sebastiani.

Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.

Effects of Weighted Hula-Hooping Compared to Walking on Abdominal Fat, Trunk Muscularity, and Metabolic Parameters in Overweight Subjects: A Randomized Controlled Study.

Natural course of NAFLD and type 2 diabetes in HIV-positive subjects with and without combination antiretroviral therapy (cART)-associated lipodystrophy: a 16-year follow-up study.

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial.

Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers.

Diabetes, liver cancer and cirrhosis: What next?

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars.

Diagnosis of nonalcoholic fatty liver disease (NAFLD).

Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) - an 11-Year Prospective Study.

Fat accumulates preferentially in the right rather than the left liver lobe in non-diabetic subjects.

Serum insulin bioassay reflects insulin sensitivity and requirements in type 1 diabetes.

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL: one-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.

Gene expression profile of subcutaneous adipose tissue in BMI-discordant monozygotic twin pairs unravels molecular and clinical changes associated with sub-types of obesity.

Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.

Out of the frying pan: dietary saturated fat influences nonalcoholic fatty liver disease.

Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.

Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease.

The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.

Exenatide Improves Beta-cell Function up to 3 Years of Treatment in Patients with Type 2 Diabetes: a Randomised Controlled Trial.

Non-alcoholic fatty liver disease and risk of type 2 diabetes.

Non-invasive Detection of Non-alcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites.

Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.

Diagnosis of non-alcoholic fatty liver disease (NAFLD).

Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.

Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease.

Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study.

Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease.

MicroRNA-192* impairs adipocyte triglyceride storage.

Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease.

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.

Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.

Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance.

Heterogeneity of NAFLD.

Regulation of angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin.

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs (EDITION 2 randomised 12-month trial including 6-month extension).